Last reviewed · How we verify
Liraglutide+standard-of-care treatment
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion, suppress glucagon, and slow gastric emptying, used here in combination with standard diabetes care.
Liraglutide activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and slow gastric emptying, reducing blood glucose levels. Used for Type 2 diabetes mellitus (in combination with standard-of-care treatment).
At a glance
| Generic name | Liraglutide+standard-of-care treatment |
|---|---|
| Also known as | Victoza |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously inhibiting glucagon release when blood glucose is elevated. This dual action, combined with delayed gastric emptying and reduced appetite, leads to improved glycemic control. When combined with standard-of-care treatment, it provides additive benefit in managing type 2 diabetes and potentially reducing cardiovascular risk.
Approved indications
- Type 2 diabetes mellitus (in combination with standard-of-care treatment)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
- Headache
- Injection site reactions
Key clinical trials
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Anti-obesity Pharmacotherapy and Inflammation
- Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity (PHASE4)
- EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (PHASE4)
- 3mg Liraglutide for Overweight or Obesity
- Obesity Treatment to Improve Diabetes (NA)
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: